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Objectives: There are few studies in Spain about outcomes at six months in 
terms of health-related quality of life (HRQoL) in patients hospitalized by heart 
failure (HF). The objective of the study was to evaluate changes in HRQoL from 
baseline to six months post discharge in patients with HF through three ques-
tionnaires, SF-12, EQ-5D-3L and Minnesota Living with Heart Failure questionnaire 
(MLHFQ). MethOds: This is a prospective study with 976 patients admitted by HF. 
Patients completed questionnaires during their hospitalization and at six months. 
The MLHFQ is a specific instrument which has 21 items with an overall scale, physi-
cal (8 items) and emotional (5 items) subscales. MLHFQ items are scoring from 0 
(best) to 5 (worse). Total score ranges from 0 to 105, physical domain from 0 to 40 
and emotional from 0 to 25. SF-12 has two dimensions, Physical Summary Score 
(PCS) and Mental Summary Score (MSC) which scores range from 0 (worst) to 100 
(best). EQ-5D has been measured according to the Spanish tariffs by time trade-off 
and the visual analogic scale. We used general linear model to study gains in each 
dimension adjusted by baseline score, age, gender and readmissions in the previous 
6 months. Results: Mean age was 76.0 (SD= 10.4), there were a 53.3% of men and 
33.1% of readmissions in the previous six months. Regarding all questionnaires and 
dimensions, baseline status influence in gains, the worse the baseline the more 
the gains. Likewise men have greater gains and patients readmitted lower in all 
domains. Age has an influence in all domains but emotional dimension of MLHFQ 
and MSC of SF-12. cOnclusiOns: Adjusted by baseline score and readmissions, 
men have greater improvements in all domains of MLHFQ, SF-12 and EQ-5D. On the 
other hand, the younger the patients the higher the improvement is, however age 
does not have any influence in psychological domains.
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Objectives: Warfarin anticoagulation is monitored using international normal-
ized ratio (INR); specified with the narrow/wide 2.0–3.0/1.9–3.5 therapeutic target 
range, and converted to time in the therapeutic range (TTR, total percentage of 
time the INR reading is within the INR therapeutic range). We explored the impact 
of I) INR monitoring and II) TTR on patients’ quality of life (QoL). MethOds: A 
total of 647 unselected patients visiting 3 health centres in Pirkanmaa district 
(31.01–11.02.2011), Finland participated to prospective study. To assess INR moni-
toring or TTR and QoL, Beta regressions were applied in Stata and EQ-5D-3L-based 
QoL (Smithson&Verkuilen transformation) 3 months after the baseline visit was 
the dependent variable. The covariates were CHADS2(congestive heart failure, 
hypertension, age> 75, diabetes mellitus, stroke) score, other comorbidities, 
baseline QoL, time difference (days) between dependent variable measurement 
and mean TTR time point (subgroup model), and INR monitoring (yes/no in total 
population) or TTR % (subgroup model). Results: A total of 28 patients (46.43% 
male; means: age 73.21 years, CHADS2-score 2.39, other comorbidities amount 
1.71, baseline QoL 0.8334, INR tests 4.21, 66.31%/82.86% INR measurements on 
the narrow/wide range) had INR measurements (“warfarinization group”) during 
the 3 months follow-up. 27 patients had calculable TTR (Rosendaal method) that 
was 69.29%/86.66% on the narrow/wide range. In the beta regression (N 393, +1 
marginal change), CHADS2-score (-0.021), other comorbidities amount (-0.030), 
baseline QoL (+0.350), and INR monitoring (p= 0.299, -0.042, SE 0.044) predicted QoL. 
The mean adjusted QoL with/without INR monitoring in the warfarinization-like 
group was 0.794/0.836. In subgroup Beta regression including only warfariniza-
tion patients, higher TTR levels predicted lower QoL (p< 0.050, +1 %-unit marginal 
change -0.006 [SE 0.007]; discrete change -0.284 in the wide range from 35.3% to 
100.0%). cOnclusiOns: INR monitoring may predict QoL loss and, surprisingly, 
higher TTR predicts lower QoL. Larger studies are needed to confirm the potential 
relationship between TTR and QoL.
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Objectives: Assess health-related quality of life (HRQoL) of patients with 
CAD. MethOds: The main observational study cohort enrolled consecutive patients 
admitted in ICU at tertiary care hospital and diagnosed with CAD. Demographic 
information, risk factors for CAD, and angiographic findings were collected. EQ-5D 
was administered at 1-year follow-up. EQ-5D levels were dichotomized: ‘no prob-
lems’ (level 1), ‘any problem’ (levels 2 and 3). Linear stepwise regression was used 
to assess predictors of all 5 health states (mobility, self-care, usual activities, pain/
discomfort, anxiety/depression). The independent variables studied include age, 
hypertension, diabetes, CHF, gender, prior MI, final diagnosis, MI type, and final 
treatment. Respondents reporting problems EQ-5D dimensions were stratified by 
presence of diabetes and compared. Results: Of 960 CAD patients enrolled for the 
main cohort study (30% diabetic), 306 (male, 230; diabetics, 64) responded HRQoL 
questionnaire at 1-year. On liner regression, presence of diabetes was independent 
predictor of 4/5 EQ-5D HRQoL dimensions: mobility (p= 0.019), problems performing 
usual activities (p= 0.041), pain/discomfort (p< 0.001); anxiety/depression (p= 0.001). 
At 1-year, mean EQ-5D utility index score and VAS score were significantly lower 
for diabetes vs non-diabetics (0.76±0.13 vs. 0.83±0.15, p= 0.0003 and 67.8 ± 8.8 vs. 
73.6±5.4, p= 0.0001, respectively) with more problems with performing usual activi-
ties (56.3% vs. 41.3%, p= 0.04), pain or discomfort (51.6% vs. 17.8%, p= 0.0001) as 
well as anxiety/depression (32.8% vs 14.9%, p= 0.002). cOnclusiOns: Among CAD 
This was especially evident for SPC patients in the 40~64 year age group (0.71 for SPC, 
0.69 for FC) and patients with two or more comorbidities (0.73 for SPC, 0.69 for FC) (P= 
0.0011). However, no statistical significance was observed for the difference both in 
persistence and the BP change between the two groups. cOnclusiOns: Our study 
suggests that compliance tends to be improved by the use of SPC compared with 
FC. Unlike the previous western studies, it was hard to find a significant increase in 
persistence or BP change with SPC therapy in this study.
PCV132
health related QualIty of lIfe and deVICe-aCCePtanCe In PatIents 
wIth ImPlantaBle CardIoVerter-defIBrIllators and telemonItorIng
Leppert F.1, Siebermair J.2, Kääb S.2, Greiner W.3
1Bielefeld University, Bielefeld, Germany, 2University of Munich, Munich, Germany, 3School of 
Public Health, Bielefeld University, Bielefeld, Germany
Objectives: Telemedical systems (TMS) and data management for implantable 
cardioverter-defibrillators (ICD) promise to reduce costs and optimize patient 
care. Depressive symptoms are common among patients with an ICD and the 
health related quality of life (HRQoL) is affected by the underlying disease and the 
implanted device, respectively. TMS might improve the HRQoL of patients and ICDs 
acceptance due to closer monitoring and, thereby, an increased level of perceived 
safety. In this RCT, changes in the level of depression, HRQoL and ICD-acceptance 
over a period of six months after ICD-implantation were investigated. MethOds: 
A total of 161 patients (80.7% male; age: 64,1±14,6; 82% with coronary disease, 11% 
with DCM) with an ICD were randomized at the day of implantation into interven-
tion (n= 82) or control group (n= 79). The intervention group was equipped with a 
telemonitoring-system that transferred ICD-data from the patients’ home to the 
medical practitioner. The control group received regular care. Patients were asked to 
fill out three questionnaires (the generic EQ-5D, the depression specific HADS and 
the device specific FPAS); the follow-up period was six month, with postal surveys 
on a monthly basis. Results: Nine patients dropped out before survey comple-
tion. A total of 140 patients filled out at least two sets of questionnaires and were 
included in the analyses. After six months the mean improvement in the HRQoL 
(EQ-5D-Index) in the telemonitoring group was 10.7 points compared to baseline 
(p= .006) while the mean change in HRQoL in the control group was 5.5 (p= .138). FPAS 
and HADS-D showed small but non-significant advantage for the telemonitoring 
group. cOnclusiOns: Preliminary results suggest that TMS have the ability to 
improve HRQoL of patients with ICDs. Results on effects towards depression and 
anxiety and enhancement of ICDs acceptance are also promising. Since ICDs are 
used in chronic diseases a longer follow-up period seems to be required to validate 
the effects.
PCV133
further ValIdatIon of a new QuestIonnaIre to measure satIsfaCtIon 
wIth medICal Care In PatIents wIth atrIal fIBrIllatIon (safuCa) In 
sPaIn
Ruiz M.A.1, Villasante F.2, González-Porras J.R.3, Franco E.4, Aranguren J.L.5, Tuñón J.L.6, 
González-López T.J.7, De Salas-Cansado M.8, Collados C.8, Pardo A.9, Soto J.8
1Autonoma University, Madrid, Spain, 2José Marvá, Madrid, Spain, 3Universitary Hospital of 
Salamanca, Salamanca, Spain, 4San Carlos Hospital, Madrid, Spain, 5Clínica Madrid, Madrid, 
Fuenlabrada, Spain, 6Universidad Autónoma de Madrid, Madrid, Spain, 7Hospital Universitario 
de Burgos, Burgos, Spain, 8Pfizer S.L.U, Alcobendas, Spain, 9Universidad Autonoma de Madrid, 
Madrid, Spain
Objectives: To assess convergent and divergent validity of a new questionnaire 
(SAFUCA) developed to measure satisfaction with medical care in patients with 
non valvular atrial fibrillation. MethOds: The 25-item reduced version instru-
ment was administered along with the Treatment Satisfaction Questionnaire for 
Medication (TSQM), and 5 Visual Analog Scales (VAS) measuring: Health Related 
Quality of Life (HRQoL), Effectiveness and Overall Satisfaction assessed by the 
patient; and Effectiveness and Tolerability assessed by the clinician. A convenience 
sample of 230 patients recruited at 7 health centers (5 hospitals and 2 primary care 
centers) in Spain was used. Second Order Exploratory Factor Analysis (SO-EFA) and 
correlation with VAS scales were computed. Results: SAFUCA dimensions cor-
related (p< 0.001) higher with corresponding TSQM dimensions (e.g.: Effectiveness 
r= 0.450, Convenience r= 0.457, Undesired Effects r= -0.340, Overall satisfaction 
r= 0.651), while SO-EFA made evident differences regarding the assessment of 
satisfaction with INR controls, interference in QoL and Medical Care. Correlation 
pattern between VAS scores was significantly different between primary care cent-
ers and hospitals, with a higher correlation between patient and clinician scores 
observed in primary care (e.g.: Effectiveness rPC= 0.430 vs. rH= 0.057). Similarly, 
correlation patterns between VAS concurrent scales and SAFUCA dimensions 
differed between center types. While high correlations between Effectiveness 
dimension and patient satisfaction VAS were observed in both cases (rPC= 0.521 
vs. rH= 0.516), correlation of Tolerability with Undesired Effects differed between 
centers (rPC= -0.474 vs. rH= -0.085). cOnclusiOns: The 25-item questionnaire 
exhibits good convergent and divergent validity values. Differences between 
types of health care centers in correlation patterns were meaningful and worth 
of further research.
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(NOACs), 5.2% on antiplatelets (AP) and 11.0% on VKA+AP combinations. In the 
“convenience” dimension, the overall score (0-100 range) was 82.9 ±17.3. The score 
was higher in the NOAC group (88.1 ± 13.0) compared to the VKA (82.1 ± 17.5), AP (87.0 
± 17.9) or VKA +AP groups (83.2 ± 16.8), respectively. In the “anticoagulant treatment 
satisfaction” dimension of the PACT-Q2, the overall score was 63.4 ±15.9. Again, 
this score was higher in the NOAC group (66.6 ±16.6) compared to the VKA (63.2 
±15.9), AP (63.7 ±16.8), or VKA + AP groups (62.8 ±15.0), respectively. cOnclusiOns: 
Overall, patients on current anticoagulation achieve relatively high values on the 
convenience scale, but moderate values on the satisfaction scale. While differences 
in group size and patient characteristics need to be taken into account, patients 
on NOACs compared to patients on VKAs tend to rate their convenience and treat-
ment satisfaction higher.
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Objectives: Aim of the study was to investigate whether chronic patients are 
willing to pay an extra amount of money in order to switch to another drug that it 
is either on patent, more effective or simpler in dose. MethOds: A cross-sectional 
study was conducted among 1600 chronic patients suffering from diabetes, hyper-
tension, COPD and Alzheimer. Logistic regression analysis was carried out to explore 
the factors that influence patients’ decision on willingness to pay (WTP) for an 
alternative drug with innovative characteristics. Results: Of the 1600 patients 
approached, 1594 responded to the survey (99.6%). A total of 40% stated that they 
would be willing to pay more for a patent drug, 57.5% for a more effective drug and 
37.5% for a simpler in dose drug. The average additional amount per month that 
they would be willing to spend was estimated at 23.6€ for a patent drug, 24.1€ for a 
more effective drug and 21.9€ for a simpler in dose drug. Statistical analysis revealed 
that WTP for a patent drug was statistically significant related with the patient’s 
income (OR,1.24;95%CI, 1.14-1.34) while WTP for a more effective or a simpler in dose 
drug was positively related with the patient’s income (OR,1.25;95%CI, 1,13-1,39 and 
OR, 1,14;95%CI, 1.05-1.24 respectively) and educational level (OR,1.06;95%CI, 1,01-
1.13 and OR, 1.06;95%CI, 1.01-1.13, respectively). cOnclusiOns: Half of chronic 
patients demonstrate absolute willingness to increase spending for an innovative 
drug, which highlights the significance they attribute to pharmaceuticals for the 
management of their condition. The remaining’s 50% reluctance may be attributed 
to the extended trust on their current pharmaceutical treatment and to the efforts 
and money spent in order to control their condition. However, patients with higher 
socioeconomic status are more likely to express WTP which reflects the economic 
burden imposed by chronic conditions, and the role of education in shaping patient 
attitudes.
CardIoVasCular dIsorders – health Care use & Policy studies
PCV143
eValuatIon of the length of hosPItal stay for PatIents wIth atrIal 
fIBrIllatIon
Volz F.1, Kloss S.1, Muschaweck F.2, Wilke M.3, Leverkus F.1
1Pfizer Deutschland GmbH, Berlin, Germany, 2Bristol-Myers Squibb GmbH & Co. KGaA, Munich, 
Germany, 3Dr. Wilke GmbH, Munich, Germany
Objectives: Identification of differences in the length of hospital stay for patients 
with atrial fibrillation (AF) with and without oral anticoagulation (OA). Longer 
stays of patients could lead to an economical burden for the hospital because 
of the Diagnosis Related Groups (DRG) system in Germany and the compensa-
tion with case-based lump sum. MethOds: We conducted a retrospective study 
using an electronic DRG benchmarking database. This database contains DRG 
data from 208 hospitals in Germany with over 2,800,000 inpatient cases per year. 
In total, 10,912,922 cases from the year 2010 to 2012 were analyzed. 661,845 cases 
fulfilled the inclusion criteria and were analyzed according the statistical analy-
sis plan including matched pair analyses. Results: Cases with AF and surgical 
intervention compared to cases without AF and with surgical intervention have 
a significantly longer pre-operation length of stay (+0.74 days) and a significantly 
longer hospital stay (+1.5 days). Furthermore cases with chronic AF (= AF+OA) 
have a significantly longer total length of stay in the hospital (+0.86 days). For 
the cases with AF and bleeding vs. cases without bleeding, there is no significant 
difference in the total length of stay, but there is a significantly longer stay of 0.82 
days compared to the average length of stay in the DRG-catalogue. cOnclusiOns: 
Patients with AF and with or without OA could be an economic burden for the 
hospital, because the increased length of stay in hospital leads to higher costs 
whereas the existing compensation diagnosis-based lump sum is not affected by 
increased treatment days. The new oral anticoagulants could lead to shorter stays 
of patients with AF by shortening the bridging periods compared to OA like vitamin 
K antagonists. Further studies should be conducted to figure out the causes for 
longer hospital stays of patients with AF.
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patients with diabetes, HRQoL was lower across all health dimensions measured 
by the EQ-5D; except mobility and self-care. Individualised therapeutic manage-
ment programs could be considered in order to improve the HRQoL of CAD patients 
with diabetes.
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Objectives: Patient Perception of Arrhythmia Questionnaire (PPAQ) is a disease-
specific questionnaire designed to measure symptoms and health-related quality of 
life in patients suffering from a group of arrhythmias collectively called supraven-
tricular tachycardias (SVT). There is no valid translation of PPAQ available in Poland, 
which hinders research in this area with Polish arrhythmia patients. The aim of 
this study was to conduct initial content validity testing through translation and 
cultural adaptation of the English language version of the PPAQ to the Polish lan-
guage. MethOds: The whole project was conducted according to ISPOR Principles 
of Good Practice for the Translation and Cultural Adaptation Process for Patient-
Reported Outcomes (PRO) Measures published in 2005. Results: In 2011, the PPAQ 
was translated into Polish and cultural adaptation was performed on 20 patients 
with SVT (12 male, age 54.9±17.4). Issues concerning close meanings of symptom 
names and language-dependant gender-related distinctions were identified. The 
former was solved by cooperation with experts in arrhythmia and latter by incor-
porating patients’ preferences during cognitive debriefing. cOnclusiOns: The 
Polish translation was well accepted by patients during this translation and initial 
content validity testing. Issues arisen during the translation process may recur in 
other translations and be resolved in similar manner.
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Objectives: Atrial fibrillation (AF) 5-folds stroke risk, which results in death or dis-
ability in 80% of individuals and one-year mortality approaches 50%. The objective of 
the present study was to analyze the health-related quality of live (HRQoL) one year 
post-stroke in patients with or without AF and the burden of caregivers. MethOds: 
We performed an observational, multicenter, naturalistic and prospective study that 
included 16 stroke units from different Spanish regions. We used EQ-5D and VAS to 
test patients HRQoL and Zarit Burden Inventory to estimate the caregiver burden. 
We collected information at hospital entry for patients, 3 and 12 months post-
stroke both for patients and carers through direct physician interviews. Results: 
A total of 321 stroke patients were recruited, 160 with and 161 without AF. EQ-5D 
was completed by 274 patients - 127 with AF and 147 without AF -, and VAS by 249 
- 113 with and 136 without AF -. The average utility scores of EQ-5D were 0.57, 0.62, 
and 0.65. We found a statistically significant difference between AF and non-AF 
obtained at hospital entry (p= 0.029) and 12 months post-stroke (p= 0.023). There 
were no differences between hospital visits (p= 0.112). If we took into consideration 
the age of patients, the absence or presence of AF in EQ-5D scores, lost its signifi-
cance (p= 0.099). VAS average scores were 45.81, 44.15 and 45.74. VAS results showed 
non-significant differences neither by AF presence (p= 0.396) nor time (p= 0.613). 
Caregiver burden was higher in AF than non-AF patientes (46.47 vs 40.93 2nd visit 
and 45.29 vs 38.73 3rd visit) and the difference was statistically significant (p= 0.007 
and p= 0.002). cOnclusiOns: Stroke has a deep impact on patients HRQoL with 
no improvement over time. In the same line, caregivers also support an important 
burden related to stroke and specially in AF patients.
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Objectives: The great majority of patients with atrial fibrillation (AF) require anti-
coagulation in order to prevent strokes or other thromboembolic events. We aimed 
at obtaining detailed and current information on patients’ satisfaction with their 
ongoing anticoagulation treatment. MethOds: PREFER in AF (The PREvention oF 
thromboembolic events – European Registry in Atrial Fibrillation) is a current non-
interventional study performed in France, Germany, Austria, Switzerland, Italy, 
Spain and UK. A total of 7243 consecutive patients with ECG-confirmed AF in the 
previous 12 months are followed up prospectively. The ‘Perception of Anticoagulant 
Treatment Questionnaire’ is a valid and reliable instrument that allows the assess-
ment of patients’ expectations (PACT-Q1) and satisfaction regarding anticoagu-
lant treatment, as well as patients’ opinion about treatment convenience of use 
(PACT-Q2). Results: A total of 5049 patients (69.7%) received antithrombotic treat-
ment and were willing to fill out the PACT-Q2 questionnaire at baseline. 77.1% 
of these were on vitamin K antagonists (VKAs), 6.4% on new oral anticoagulants 
